For reference: fatigue · semaglutide · STEP 5.
I have the document in front of me and I can read the numbers. What I cannot do is interpret them.
I am reasonably comfortable with statistics and completely uncomfortable with chromatography, or vice versa.
Which parts of this are informative and which are decoration?
It helps to be literal here: the incidence figures are dose-related but the timing is escalation-related, and conflating the two produces most of the bad advice in this area. Adverse events cluster in the one to two weeks following each dose increase, then decay.
Nausea incidence in the pivotal trials runs to roughly 40 to 45 per cent at the higher doses against 15 to 20 per cent on placebo, with vomiting at roughly 15 to 25 per cent against 5 to 8 per cent. Discontinuation specifically attributable to gastrointestinal adverse events was in the range of 4 to 7 per cent. Those are the numbers to hold in mind when someone describes their experience as unusual.
| Feature | Local reaction | Sterile abscess | Cellulitis |
|---|---|---|---|
| Onset | Hours to 2 days | Days | 1–4 days, progressive |
| Warmth | Absent or minimal | Mild | Marked |
| Expansion | Static or shrinking | Slow | Expanding |
| Texture | Firm, flat or raised | Fluctuant | Diffuse, indurated |
| Systemic features | None | None | Fever, malaise possible |
| Action | Observe, rotate site | Clinical review | Same-day clinical review |
The telogen effluvium timing signature is the diagnostic feature: hair enters the shedding phase two to four months after the insult, so shedding that starts at month three of rapid loss and peaks around month four to five is the expected pattern. Shedding that starts in week two is not telogen effluvium and warrants a different question. In either case the follicle is not destroyed and regrowth is the rule.
The pooled gastrointestinal adverse-event rates across the STEP programme and the SURMOUNT programme are reported in the primary publications and in the FDA and EMA assessment reports, and the assessment reports are more useful because they give the placebo-arm rates alongside the active-arm rates in the same table.
Write down in advance which symptoms mean stop and seek care. It is a short list and it is much easier to write when you are well.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsLook at the placebo arm before concluding anything about attribution. The placebo-arm rates for most of these events are not small, because the events themselves are common in the underlying population.
Pancreatitis red flags worth memorising rather than looking up: severe, persistent epigastric pain radiating to the back, worse lying flat and better sitting forward, with nausea and vomiting that does not settle. That combination is an urgent assessment, not a dose adjustment. An isolated lipase elevation without that picture is common and usually not pancreatitis.
The underlying point is that vomiting matters mostly through its consequences. Loss of gastric fluid depletes sodium, chloride and potassium, and hypokalaemia presents as exactly the fatigue and cramping people attribute to the drug. Persistent vomiting also makes a renal panel uninterpretable, because a pre-renal picture looks like renal impairment.
If the timing does not fit the escalation, look for another explanation before settling on the drug.
Worth being precise here: timing is the most useful diagnostic feature here and it is the one most often omitted from the question.
Fatigue attribution is a subtraction problem. Take out the energy deficit, the dehydration, the electrolyte shortfall and the poor sleep, and what remains attributable to the drug in the trials was modest — placebo-arm fatigue rates were within a few points of active-arm rates in most of the programme. The corollary is that the fixable causes are usually the actual causes.
The gallbladder signal tracks the rate of weight loss more than it tracks the drug. Rapid mobilisation of adipose tissue increases biliary cholesterol saturation and reduces gallbladder motility; that combination is lithogenic whether the loss came from a drug, a very-low-energy diet or bariatric surgery. The drug contribution on top of that is present but smaller than the rate contribution.
Pooled analyses of gallbladder-related events with GLP-1 receptor agonists find a modest increase in relative risk, with the effect larger at higher doses and longer durations — consistent with a rate-of-loss mechanism as much as a direct one[1].
Fix the fixable causes first — fluid, electrolytes, sleep, intake — before concluding that the compound is responsible.
The honest framing is that this is very common, usually self-limiting, and occasionally the presentation of something that is not self-limiting at all — and the differentiating features are specific enough to be worth knowing.
Early satiety is not a side effect; it is the mechanism being observable. The useful distinction is between satiety, where you stop eating without distress, and aversion, where the thought of food is unpleasant. The first is the intended effect. The second frequently precedes the dose being too high or escalated too fast.
Worth being explicit: nothing here is medical advice, and research-use-only compounds are not approved for human use.
Most of this resolves. The point of knowing the pattern is to recognise the small fraction that does not.
edited 31 Oct 2025 by Dr_Colm_Fitzhenry — expanded the table to cover the lower concentration
The mechanism explains the pattern. Delayed gastric emptying plus central appetite suppression produces early satiety, and early satiety plus a slowed transit produces exactly the symptom cluster people report.
Injection-site reactions are more often diluent-related than peptide-related. Benzyl alcohol sensitivity is uncommon but real, and it presents as a consistent local reaction at every site with a preserved diluent and no reaction with an unpreserved one — which is a straightforward thing to establish. Injection depth is the other common cause: intradermal placement stings and welts, subcutaneous placement usually does not.
Telogen effluvium following substantial weight loss is documented independently of any pharmacotherapy, which is the cleanest argument that the rate of loss rather than the agent is the primary driver.
One qualification — reported incidence in a monitored trial population is a lower bound on what happens in an unmonitored one, because trial participants were escalated to protocol and supported through it.
A symptom diary with dates against dose steps answers most of these questions without anyone needing to guess.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.